<DOC>
	<DOCNO>NCT02463825</DOCNO>
	<brief_summary>Amyotrophic lateral sclerosis ( ALS ) neuromuscular disease result rapid decline normal muscle function tone lead difficulty mobility , eating , drinking , breathing , sleeping , communicate . The disease progressive cure currently exist . Most people diagnosed ALS succumb within 3 5 year . The approved treatment slow progression ALS call RilutekÂ® ( riluzole ) modest effect show increase survival month . Muscular dysfunction present people ALS cause nerve breakdown dysfunction communication muscle nerve . The area communication occur call neuromuscular junction . Some recent study focus use different medication enhance communication neuromuscular junction goal improve muscle function result . This approach unproven may help slow progression disease . Pimozide medication demonstrate enhance communication neuromuscular junction fish mouse . This study look whether Pimozide may help slow progression ALS much medication need take effect .</brief_summary>
	<brief_title>A Registry-Based Clinical Trial Pimozide Patients With Neuromuscular Junction Transmission Dysfunction Due ALS</brief_title>
	<detailed_description>This clinical trial two component : acute therapy component consist Phase II placebo-controlled , double-blinded , randomized-controlled pilot study pimozide treatment ALS ; second component feature longitudinal follow-up study ALS progression outcomes . This clinical trial registry-based include subject recruitment facilitate Canadian Neuromuscular Disease Registry ( CNDR ; National Principal Investigator : L. Korngut ) , longitudinal follow-up data collection occur second component clinical trial CNDR . The acute therapy study duration subject around 11 week . The follow study duration CNDR 5 year . Number study participants:25 Randomization : Subjects block randomize block size five subject . Within block one subject randomly assign placebo remain four subject randomize treatment group . Study physicians blind patient randomization status . Randomization occur 4:1 ratio study drug ( 20 subject ) placebo ( 5 subject ) . After administration maximum dose 45-50 day , subject taper allocate treatment placebo . Randomization occur via permuted block randomization study personnel blind randomization time allow full concealment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pimozide</mesh_term>
	<criteria>1 . Patients classify clinically definite , clinically probable , clinically probable ( laboratorysupported ) ALS accord ElEscorial diagnostic criterion ALS 2 . Evidence decremental response great equal 5.0 % least one nervemuscle pair initial screen visit 3 . Age 18 year great 4 . Consent participate Canadian Neuromuscular Disease Registry ( CNDR ) ( followup study component ) . 1 . Diagnosis clinically possible clinically suspect ALS define ElEscorial diagnostic criterion ALS 2 . If subject take riluzole dose must stable 30 day prior randomization visit . Riluzole initiate study . 3 . History Parkinson 's disease 4 . History traumatic brain injury 5 . History neuroleptic malignant syndrome 6 . History hypersensitivity serious adverse reaction ( ) neuroleptic medication 7 . History prolong QTc interval &gt; 500 m 8 . History hyponatremia &lt; 130 mmol/L 9 . History current heparin warfarin use 10 . History hepatic and/or renal impairment may affect pimozide metabolism 11 . History current pregnancy breastfeed 12 . Current antipsychotic use 13 . Presence central nervous system depression , comatose state , liver disorder , renal insufficiency , blood dyscrasia 14 . Presence depressive disorder Parkinson 's syndrome 15 . History congenital long QT syndrome family history syndrome patient history cardiac arrhythmia Torsade de Pointes 16 . Presence acquire long QT interval , associate concomitant use drug know prolong QT interval 17 . Presence hypokalemia hypomagnesemia 18 . Presence clinically significant bradycardia ( heart rate &lt; 50 beat per minute ) 19 . The concomitant use CYP 3A4inhibiting drug azole antimycotic , antiviral protease inhibitor , macrolide antibiotic nefazodone 20 . The concomitant use CYP 2D6inhibiting drug quinidine also contraindicate 21 . Concomitant use serotonin reuptake inhibitor , , sertraline , paroxetine , citalopram escitalopram 22 . Severe dysphagia risk aspiration 23 . Has take compound current know future study potential therapy ALS le 30 day prior dose OR history exposure stem cell therapy treatment ALS time</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>